Hu et al. has highlighted the potential of DDR1 inhibitors as radiosensitizing agents in head and neck squamous cell carcinoma, where DDR1 overexpression is linked to immune evasion and poor prognosis [56]. This evidence concerns the gene DDR1 and head and neck squamous cell carcinoma.